Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAICI (Adebrelimab + FOLFOX) as Neoadjuvant for Resectable HCC
NCT06741020Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Mar 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06741020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741020.